



LABORATORY REPORT

NAME : MR.PR0043	REFERRED BY : SELF	VISIT NO : VAMP26148111
AGE : 40Y 0M 0D	ZERO TARIFF CLIENT CODE	COLLECTED ON : 21-04-2026 10:00
GENDER : Male	LAB MR# : AAMP01479390	RECEIVED ON : 21-04-2026 18:11
OP / IP / DG # :		APPROVED ON : 22-04-2026 19:51
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Hepatitis Panel - Acute Screen-I

SEROLOGY AND IMMUNOLOGY

Hepatitis A virus (HAV) IgM (Serum)

Hepatitis A virus (HAV) IgM ELISA	0.09	Negative : <0.8 Equivocal : 0.8-1.2 Positive : >1.2	Index
--------------------------------------	------	---	-------

Interpretation:

Hepatitis A Virus (HAV) is a RNA virus of Picornavirus family transmitted by fecal- oral route. Infection with HAV is self limiting though 5-10% cases may show a secondary rise in enzymes. Since symptomatic Hepatitis A virus infections are clinically indistinguishable from Hepatitis B or C virus, serological testing is an extremely important tool to achieve proper diagnosis. During the acute phase of HAV infection, IgM appears in patient's serum in nearly all cases at the onset of symptoms, peaks within the first month of illness and persists for 3-6 months. It declines to undetectable levels within 12 months. The most effective diagnostic determination of HAV acute infection is the detection of Anti HAV- IgM. Patients exhibiting Borderline Reactivity should be monitored at weekly intervals. This will distinguish rising Anti HAV- IgM levels associated with Acute Hepatitis A infection from decreasing or unchanging levels associated with recovery. Rheumatoid factor can give rise to false positive results. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy.

Hepatitis B surface antigen (HBsAg) - Screening (Serum)

HBsAg CLIA	0.02	Non-reactive : <0.05 Reactive : >0.05	IU/mL
---------------	------	--	-------

Interpretation:

HBsAg is the first marker to appear after Hepatitis B infection and may be observed 2 or 3 weeks before the clinical and biological symptoms of the disease appear. Its period of presence may be very short (a few days) or very long (several years). HBs Ag persisting beyond 6 months in the serum denotes "chronic hepatitis". Because of the existence of numerous asymptomatic chronic carriers, hepatitis B represents an important transfusion hazard and the prevention of the transmission is based upon the detection of the HBs Ag at the time of each blood donation. This is a screening test and all positive samples must be confirmed by confirmatory tests like Neutralization assay or PCR. False positive results can be obtained due to the presence of other antigens or elevated levels of Rheumatoid factor (RF), although this is seen in less than 1% of the samples tested.

Hepatitis B core Antibody IgM (Anti HBc - IgM) (Serum)

Anti HBc - IgM ELISA	0.28	Negative : <1.00 Positive : >1.00	Index Value
-------------------------	------	--------------------------------------	-------------

Interpretation:

A positive result indicates recent acute hepatitis B infection. A negative test result does not exclude the possibility of exposure to hepatitis B virus. Anti- HBc IgM is the earliest specific antibody appearing usually within 2 weeks after HBsAg. It is found in high titres for a short period during the acute phase that covers the serologic window and declines to low levels during recovery. It may be detectable upto 6 months. Results from immunosuppressed patients should be interpreted with caution. Testing additional HBV markers is recommended for the final diagnosis of the infection, in those very particular cases.





LABORATORY REPORT

NAME	: MR.PR0043	REFERRED BY	: SELF	VISIT NO	: VAMP26148111
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479390	RECEIVED ON	: 21-04-2026 18:11
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 19:51
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
Hepatitis Panel - Acute Screen-I			

Dr. G. Amitha
MBBS, MD (MICROBIOLOGY)
Consultant Microbiologist

Disclaimer:

1. All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
2. Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
3. Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
4. Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
5. Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
6. Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
7. Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
8. If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

